Oculis (NASDAQ:OCS) Earns Outperform Rating from Analysts at Lifesci Capital

Lifesci Capital assumed coverage on shares of Oculis (NASDAQ:OCS) in a report released on Wednesday, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $55.00 price objective on the stock. Lifesci Capital also issued estimates for Oculis’ Q4 2025 earnings at ($0.44) EPS, FY2025 earnings at ($1.72) EPS, Q1 2026 earnings at ($0.40) EPS, Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.42) EPS, FY2026 earnings at ($1.62) EPS, FY2027 earnings at ($1.44) EPS, FY2028 earnings at ($1.32) EPS and FY2029 earnings at ($2.26) EPS.

A number of other research analysts also recently weighed in on the stock. HC Wainwright increased their price objective on shares of Oculis from $36.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, November 11th. Needham & Company LLC restated a “buy” rating and issued a $36.00 price target on shares of Oculis in a research note on Tuesday, November 11th. Chardan Capital reiterated a “buy” rating and set a $51.00 price objective on shares of Oculis in a research report on Tuesday, November 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Oculis in a report on Wednesday, October 8th. Finally, Bank of America cut their price target on Oculis from $30.00 to $29.00 and set a “buy” rating for the company in a research note on Thursday, November 13th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $42.33.

Oculis Stock Up 10.1%

Oculis stock opened at $21.68 on Wednesday. Oculis has a 12 month low of $14.00 and a 12 month high of $23.08. The stock has a fifty day simple moving average of $19.77 and a two-hundred day simple moving average of $18.77. The company has a current ratio of 4.47, a quick ratio of 4.47 and a debt-to-equity ratio of 0.02. The firm has a market cap of $1.14 billion, a price-to-earnings ratio of -8.60 and a beta of 0.32.

Oculis (NASDAQ:OCS) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.10. Oculis had a negative return on equity of 80.82% and a negative net margin of 12,915.42%.The company had revenue of $0.31 million for the quarter, compared to analysts’ expectations of $0.23 million. Equities analysts predict that Oculis will post -2.09 EPS for the current fiscal year.

Institutional Trading of Oculis

A number of hedge funds and other institutional investors have recently bought and sold shares of OCS. Woodline Partners LP raised its stake in Oculis by 65.8% during the 3rd quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock worth $1,474,000 after acquiring an additional 33,265 shares during the period. Bank of America Corp DE increased its stake in shares of Oculis by 2.2% in the second quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock worth $786,000 after purchasing an additional 878 shares in the last quarter. Bosun Asset Management LLC bought a new stake in shares of Oculis during the 2nd quarter valued at $378,000. Marshall Wace LLP purchased a new position in shares of Oculis during the 2nd quarter valued at $393,000. Finally, Geode Capital Management LLC boosted its holdings in Oculis by 27.7% in the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock worth $571,000 after buying an additional 6,384 shares during the period. Hedge funds and other institutional investors own 22.30% of the company’s stock.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.